Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.36 |
| ▸ | FABP4 | P15090 | 3/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 3/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.32 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.32 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
| ▸ | AKT2 | P31751 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4530604 | 0.76 | MAPK14 (0.51) | MAPK14FABP4FAAHCNR1CNR2 | |
| SCHEMBL29593607 | 0.72 | MAPK14 (0.66) | MAPK14CSNK1D | |
| SCHEMBL3992817 | 0.72 | MAPK14 (0.66) | MAPK14CSNK1D | |
| SCHEMBL5780689 | 0.68 | MAPK14 (0.47) | MAPK14FABP4 | |
| SCHEMBL4300771 | 0.66 | MAPK14 (0.47) | MAPK14FABP4 | |
| SCHEMBL4300769 | 0.66 | MAPK14 (0.47) | MAPK14FABP4 | |
| SCHEMBL29594245 | 0.61 | MAPK14 (0.54) | MAPK14 | |
| SCHEMBL4069800 | 0.61 | MAPK14 (0.54) | MAPK14 | |
| SCHEMBL18152791 | 0.59 | FABP4 (0.46) | MAPK14FABP4FABP5CNR1AKT1 | |
| SCHEMBL4837363 | 0.59 | MAPK14 (0.65) | MAPK14CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318443-A1 | KINASE INHIBITORS | BONJOUKLIAN ROSANNE | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318443-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | MAPK14 174/4885FABP4 4320/4885FABP5 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.